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 THE EPIDEMIOLOGY AND CLINICAL PRESENTATION OF LEPROSY IN 
THE PEDIATRIC POPULATION OF PARAGUAY 
Kattan J, Velazquez EF, Reyes-Mugica M.  Department of Pathology, Yale University, 
School of Medicine, New Haven, CT. 
  
Background:  Several aspects concerning the biology and epidemiology of leprosy 
remain unknown.  It has been recognized that the study of children with leprosy could 
provide important insight into unanswered questions, particularly if disease 
manifestations are carefully observed. 
Methods:  A retrospective chart review of 308 cases of children aged 0-14 y/o was 
conducted at the Ministry of Health Leprosy Department in Asuncion, Paraguay.  Data 
regarding age, gender, leprosy classification, transmission, detection, clinical 
presentation, presence and class of reaction, and disability were abstracted.   
Results:  The study group ranged from 2 to 14 years of age.  The incidence rate and the 
risk of having leprosy were shown to increase with age. The gender ratio of males to 
females was 1:1.  A positive contact history was documented in 86.4% of cases, with 
intrafamilial contact type accounting for 98.9% of known cases.  The average time to 
diagnosis was 1.1 years.  Paucibacillary leprosy was more common than multibacillary 
leprosy in this study population.  16.9% of children experienced some type of nerve 
involvement.  1.9% of all children presented with hypersensitivity reactions, with Type 2 
erythema nodosum leprosum reaction being the most common. 
Conclusions:  The minimum incubation period could be two years.  Children may be less 
likely to develop severe forms of leprosy.  Males and females may be equally susceptible 
to contracting the disease from a biological perspective.  Close and prolonged contact 
appears to be necessary for transmission.  Nerve involvement and hypersensitivity 
reactions are relatively uncommon in children.   
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 BACKGROUND 
 
Preface 
Leprosy, also known as Hansen’s Disease, is an ancient disease retaining a strong historic 
association with stigma. (1)  Almost everyone knows the word “leprosy,” yet fact and 
fiction related to the disease are commonly confused.  An extensive general background 
covering the biology, medical management, and epidemiology of leprosy is included as 
the disease is a lesser known entity in this part of the world.    
 
Microbiology & Pathogenesis 
Leprosy is caused by the bacterium Mycobacterium leprae.  It is an acid fast bacillus that 
replicates slowly (generation time 13 days). (1) M. leprae secretes no toxins, and its 
virulence is based on properties of its cell wall. (2) It grows optimally at <37° C, 
explaining the bacterium’s tendency to infect the cool areas of the body, such as the skin 
and the nerves close to the skin. (1)  The invading bacteria have three specific targets:  
peripheral neural tissue (Schwann cells), small vessels (endothelial cells and pericytes), 
and the monocyte-macrophage system.  The formation of granulomas is a common 
histopathologic landmark of disease. (3) 
 
M. leprae has never been successfully cultured in artificial media, severely limiting the 
progress of laboratory-based research on the disease.   However, the bacterium has been 
cultured in the foot pads of mice. (1)  Leprosy is also well-known to infect wild 
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 armadillos of the southeastern US as well as in chimpanzees and monkeys in West 
Africa. (1) 
 
Transmission 
The route of transmission has never been definitively proven.  Transmission via the 
nasorepiratory route is believed to be the most plausible mechanism.  There is less 
evidence to support transmission via skin abrasions or via fomites.  Because one study 
showed the leprosy bacilli to remain viable for up to five months after drying in the shade 
and up to six months in wet soil, the possibility of transmission via aerosolized bacilli has 
been entertained.  Transmission through breast milk and through the placenta is also a 
theoretical possibility. (1)  The possibility of a subclinical carrier state in which a subset 
of individuals can carry the disease and infect others, but not develop disease themselves 
is also an area of debate. (4) 
 
Contrary to popular believe, leprosy does not appear to be a highly contagious disease.  
In fact, most people exposed to M. leprae never develop the disease.  Evidence suggests 
that prolonged and intimate contact with a leprosy patient is likely necessary in order to 
transmit the disease. (5,6) 
 
Incubation Period 
The incubation period of M. leprae is uncertain, but is believed to be generally between 
two and five years. (7,8) However, some assert that the incubation period could be as 
short as 9 months and as long as 20 years. (9) 
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 Classification 
Two main classification systems exist in order to categorize leprosy, namely the World 
Health Organization (WHO) and Ridley-Jopling systems. 
 
The WHO system is based on the quantity of skin lesions and the number of bacilli on 
skin smear. Skin smears are made by squeezing a fold of skin and making a shallow slit 
in the skin with a razor blade or scalpel.  The instrument is then turned at a right angle to 
the slit and the sides of the slit are scraped.  The fluid obtained is spread on a slide, heat-
fixed, stained, and evaluated. (1) The two main categories of the WHO classification 
system are listed below: 
 
1) Paucibacillary leprosy (PB leprosy): ≤5 skin lesions with no bacilli on skin smears. 
 
2) Multibacillary leprosy (MB leprosy): ≥6 skin lesions and may have bacilli on skin 
smears. 
 
The Ridley-Jopling classification system is based on the histopathology of skin lesions 
and essentially represents a spectrum of disease.  The categories of the Ridley-Jopling 
system are listed below: 
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 1) Indeterminate (I) 
 
2) Tuberculoid (TT) 
 
3) Borderline tuberculoid (BT) 
 
4) Mid-borderline (BB) 
 
5) Borderline lepromatous (BL) 
 
6) Lepromatous (LL) 
 
Indeterminate leprosy is the most benign form of the disease with the least amount of 
bacilli and strong host immune response evident, while lepromatous leprosy represents 
the most severe form of disease with many bacilli present in tissue, and evidence of a 
weak host immune response.     
 
The spectrum of disease classification is not static.  For example, in some cases untreated 
tuberculoid leprosy can progress to lepromatous leprosy, given a long enough time and 
the proper immunologic environment. Nor are the two classification systems mutually 
exclusive.  Indeterminate and tuberculoid leprosy are commonly referred to as PB 
leprosy, while borderline and lepromatous leprosy are commonly referred to as MB 
leprosy. (1,10) 
 
Clinical Features 
In short, the key clinical features of leprosy are skin lesions with sensory loss and 
enlarged peripheral nerves .  A more detailed description of clinical manifestations is 
below: 
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 The skin lesions characteristic of indeterminate leprosy are vaguely defined, 
hypopigmented macules with minimal neural involvement as assessed by sensory deficit 
testing.  Tuberculoid leprosy often presents with a few well-defined anesthetic macules or 
plaques with neural involvement being more common.  Lepromatous leprosy lies at the 
opposite end of the spectrum from I and TT leprosy, commonly presenting with multiple 
macules, nodules or diffuse infiltrates as well as neural lesions later in the natural history 
of the disease.  Lepromatous leprosy produces the classic lesions and deformities 
presented in the popular media.  Borderline leprosy types presents with numerous lesions 
having distinct borders and often with neural involvement. (1) 
 
Nerve involvement can involve both sensory and motor loss.  Sensory deficits are more 
common, likely because they usually occur first in the evolution of the nerve damage 
caused by leprosy (11).  Nerve involvement of any type usually occurs in advanced 
disease in the lepromatous end of spectrum.  However, leprosy can rarely manifest itself 
solely with nerve damage and without any skin lesions.  This is referred to as pure 
neuritic leprosy.  Frequently involved nerves include the ulnar nerve at the elbow, the 
median nerve above the carpal tunnel, the radial nerve at the spiral groove, the radial 
cutaneous nerve in the lower forearm, the peroneal nerve above the fibular head, the tibial 
nerve above the ankle, and the facial nerve at the region of the zygomatic bone. (12) 
 
In severely advanced disease loss of eyebrows and nasal depression can be seen, leading 
to the characteristic leonine facies. (1,7) 
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 It should be emphasized that leprosy is not a “flesh-eating” disease, as is still portrayed in 
the popular media (13,14).  Much of the deformity associated with leprosy originates in 
the loss of sensory nerve function.  For example, a patient who loses sensation of his 
fingers and smokes cigarettes may inadvertently burn his fingers with a lighter or with the 
end of the cigarettes because of his inability to perceive pain.  Or, alternatively, an 
impoverished patient with leprosy who earns a living through manual labor may damage 
his extremities with dangerous machinery or through repetitive tasks because of his 
inability to feel.  In essence, a significant portion of the deformity associated with leprosy 
does not originate from the infecting organism per se, but rather is an indirect sequelae of 
the disease. (15) 
 
Immunology 
Leprosy can be thought of as a paradigm for understanding the range of pathologic 
interactions between variable host immune responses and a relatively stable parasite.  It is 
the immune response of the host that determines the position of the patient in the Ridley-
Jopling spectrum of disease described above. (1)  Patients who develop tuberculoid 
leprosy mount a cell-mediated immune response that is TH1 predominant, with 
production of IL-2 and IFN-γ.  On the opposite end of the spectrum, lepromatous leprosy 
patients exhibit an impaired cell-mediated TH1 immune response, with a predominant 
TH2 response, resulting in the production of IL-4 and IL-5 that activate humoral 
immunity, and result in production of antibodies. (2,3) 
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 Reactions 
Leprosy causes several unique immune reactions in the host that occur either during the 
natural course of the disease or are precipitated by administration of chemotherapeutic 
treatment.  The two most common acute reactional episodes are described below: 
 
Type I:  This reaction is also known as Reversal Reaction.  This state is thought to 
represent an episodic upgrading of cell-mediated immunity.  It is characterized by onset 
of erythema and edema of skin lesions and is also associated with neuritis, ulceration, and 
additional motor and sensory loss.   Type I Reaction is most commonly seen in borderline 
cases. (1) 
 
Type 2:  This type of reaction is also referred to as erythema nodosum leprosum (ENL).  
ENL is thought to be an immune complex disorder.  Common symptoms include rapid 
onset of tender subcutaneous nodules and fever.  It is most commonly associated with 
lepromatous leprosy. (1) 
 
Disease Susceptibility 
In those who do develop clinical manifestations, many only acquire a single lesion that is 
often self-healing. (16)  In other cases, however, the disease may progress to a more 
advanced stage.  The role of genetic factors in determining disease susceptibility remains 
uncertain.  In some ethnic groups, certain HLA-DR antigens are associated with types of 
leprosy, but not necessarily with disease susceptibility. (1) 
 
 11
 Diagnosis 
The diagnosis of leprosy is ideally made based on a physical examination and a skin 
smear or biopsy.  Physical exam should, at minimum, consist of a thorough inspection of 
the entire skin surface, palpation of peripheral nerves for enlargement and tenderness, 
sensory testing in lesions using a few fibers of cotton or calibrated nylon bristles to assess 
any deficits in light touch perception.  In resource-limited settings lacking access to 
laboratory facilities, such as rural areas in the developing world, a proper physical 
examination and history-taking is frequently considered sufficient to establish the 
diagnosis. (1) As of yet, there does not yet exist a widely-accepted, rapid, definitively 
diagnostic tool for use in the field.  Recently, several immunological and molecular 
assays for the purpose of leprosy diagnosis have been developed.  However, none, as of 
yet, have the potential for practical use in the field because they do not clearly 
differentiate between subclinical infection and disease. (17)  
 
Treatment 
Most patients today are treated with a combination of antibiotics including dapsone, 
rifampicin, and clofazimine, a standardized WHO regimen, commonly known as multi-
drug therapy (MDT). (6) 
 
With proper treatment, patients rapidly become non-contagious.  In fact, clinical and 
laboratory evidence suggest that infectiousness is lost generally within a day of starting 
treatment with multidrug therapy. (9)  Most skin lesions usually resolve with treatment.  
However, some nerve damage and physical deformities may be permanent.  The result is 
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 that people who are biologically free of infection can still carry the physical 
manifestations of leprosy, and continue to face stigma based on their physical 
appearance.  In fact, it is estimated that there are between one and two million people in 
the world who are visibly and irreversibly disabled due to past and present leprosy 
disease. (6) 
 
Epidemiology 
The global prevalence of leprosy has declined drastically over the past two decades since 
the advent of multi-drug therapy.  Since 1985, more than 14 million patients globally 
have been cured through MDT.  At the beginning of 2005, the global prevalence of 
leprosy was 286,063 cases, down from 460,000 in 2004. (18,19)  Leprosy remains a 
major public health problem in nine highly endemic countries around the world, namely 
Angola, Brazil, Central African Republic, Democratic Republic of the Congo, India, 
Madagascar, Mozambique, Nepal, and the United Republic of Tanzania.  Within the 
Americas, the three countries with the highest rates of endemic leprosy are Brazil 
(prevalence 1.7 per 10,000 population), and Guyana (prevalence 1.3 per 10,000), 
followed by Paraguay (prevalence 1.1 per 10,000 population). (18) 
 
In terms of global prevalence, it appears obvious that great strides have been made 
toward the goal of leprosy control.  The global annual incidence, however, proves more 
complicated to decipher.  Incidence can theoretically be estimated by new case detection 
rates.  However, this holds true only if a stable proportion of all existing cases are 
notified.  This assumption is clearly not met with respect to leprosy.  Geographical 
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 coverage, intensity of case-finding, re-registration of defaulted patients, and quality of 
leprosy information systems vary from country to country and have changed over time.  
Thus, it is problematic to use new case detection rates as a proxy for incidence. (20) 
 
Momentarily casting doubt aside and assuming that new case detection rates do reflect 
disease incidence, trends of global leprosy incidence over time still prove perplexing in 
other respects. (20) The 2004 global incidence measured by the number of new cases 
diagnosed in the year was 407,791.  This represents a 21% decrease since 2003, mainly 
due to a reduced number of new cases detected in India.  However, when looking at new 
detection rates in the other highly endemic countries of the world, the numbers seem to 
be stable over time, or have decreased only slightly. (18) These trends certainly do not 
reflect the accelerated decline in incidence predicted by the advent of MDT and the 
resultant massive decrease in disease prevalence once expected.  One would presume that 
with such a reduction in prevalence and therefore a decrease in the reservoir of infection 
that a sizable impact on incidence would be made, but this phenomenon was never seen.  
(20) 
 
In sum, we do know that less people around the world today suffer from overt leprosy 
than ever before.  However, the ambiguity revolving around the issue of disease 
incidence makes it difficult to say anything concrete regarding progress toward leprosy 
elimination goals. (20) 
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 Of note, the annual incidence of leprosy in the US is approximately 100, as reported by 
the Centers for Disease Control and Prevention. (21)  Most of the cases in this country 
are diagnosed principally in California, Florida, Hawaii, Louisiana, Texas, and in New 
York City and Puerto Rico.  The majority of these cases occur in immigrants and 
refugees who acquired the disease in their native countries.  However, leprosy remains 
endemic in California, Hawaii, Louisiana, Texas, and Puerto Rico. (9) 
 
Disease Control Measures 
The mainstay of leprosy control efforts involves early detection and treatment of cases, 
patient education, and evaluation of close patient contacts. (9) 
 
It should be noted that isolation of leprosy patients is not recommended.  The availability 
of effective and time-limited ambulatory treatment, with rapid elimination of 
infectiousness has limited the need for hospitalization and transformed leprosy care to an 
outpatient-based entity.  Isolating leprosy patients is of questionable value, can lead to 
stigmatization, and is not suggested. (9) 
 
Adequate public health and clinical infrastructure is also clearly an essential element of 
leprosy control measures.  WHO advocates for integration of leprosy care into primary 
care healthcare systems, rather than keeping leprosy as the domain of highly specialized, 
vertical programs.  (17) 
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 History and Stigma 
Leprosy is an ancient disease that has left behind a terrifying image of mutilation and 
stigma on the pages of history.  The disease was present in some of the oldest 
civilizations, including those of China, Egypt, and India.  Leprosy has carried with it the 
false stereotypes of being a highly contagious, flesh-eating, incurable disease.  It is often 
thought to be a curse from God and is associated with filth and sin.  Such myths and 
stereotypes still run rampant in present-day society, making social stigma an almost 
inevitable aspect of the contracting the disease. (6) 
 
M. leprae was originally discovered by G.A. Hansen in 1873.  It was, in fact, the first 
etiologic agent of a chronic disease identified in humans. (1) Leprosy treatment in the 
form of the antibiotic dapsone was introduced in the 1940s. (6) However, the effective 
combination therapy that is used today did not appear until the early 1980s. (20) 
 
Isolation of patients in leper colonies was the mainstay of disease management until the 
1900s.  Even in the US, leprosy patients were forcefully taken from their families and 
placed in colonies on Molokai, Hawaii and in Carville, Louisiana. (22,23) The days of the 
leprosaria have since been phased out.  With the advent of an effective drug therapy, 
leprosy is now largely treated on an outpatient basis.  Some colonies do still exist, but are 
not leper colonies in the old sense of the term.  Patients now come to these colonies on a 
voluntary basis.  Most stay only for a brief time for physical rehabilitation while others 
may stay on in a more permanent fashion because their families have rejected them or 
because they are disabled and have no where else to turn to for support. (6) 
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 The dark history shrouding leprosy unfortunately seems to be intractable element of the 
disease.  The language of leprosy has even persisted as a part our English lexicon, though 
the disease is rarely seen in this country.  “He was treated like a leper” We say it all the 
time without thinking.  Leprosy seems to be virtual synonym for stigma. 
 
Unanswered Questions 
Many questions remain unanswered regarding the biology and epidemiology of leprosy:  
What is the exact route of transmission?  Can infection occur through casual contact?  Do 
subclinical carriers significantly contribute to disease transmission?  Do unknown non-
human reservoirs of the disease exist?  Does the bacterium exist outside a host in the 
environment?  What is the range of the incubation period?  Why do some people develop 
severe disease while other experience self-healing lesions?  Will the bacilli ever be 
cultured in vitro?  Why is the gender ratio skewed towards males?  What is actually 
occurring in terms of the global incidence rate?  Can leprosy ever be eradicated?  
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 JUSTIFICATION OF RESEARCH 
 
Great successes have been achieved during the last decade in the global control of 
leprosy. (18) Despite these achievements, many aspects concerning the biology and 
epidemiology of leprosy remain unknown. (17,24,25) It has been well recognized that 
studies of the epidemiology and clinical presentation of leprosy in children could provide 
important insight into the biology of the disease, helping to unravel some of the scientific 
unknowns mentioned above (8,24-27) Children represent a favorable population to study 
because their environmental exposures are usually stable and known.  In ideal situations, 
parents can provide essential information including the onset and evolution of the 
disease, possible sources of exposures, etc.  In contrast, the adult population is often more 
mobile, experiencing a less predictable environment, making a clear history more 
difficult to elicit.  The majority of studies on childhood leprosy have been conducted in 
India, while far fewer have been conducted in Latin America.  Paraguay was chosen as a 
study site for this research because it is an understudied part of the world and it represents 
the third highest rate of endemic leprosy in the Americas.  
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 SPECIFIC AIMS OF THE THESIS 
   
• Describe the epidemiological characteristics and clinical features of childhood 
leprosy in Paraguay 
• Use the descriptive data to generate hypotheses regarding the biological 
characteristics of M. leprae 
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 METHODS 
 
A retrospective chart review was conducted at the Ministry of Health Leprosy 
Department in Asuncion, Paraguay.  The archived data at the Department includes 
information on all patients diagnosed with and treated for leprosy in the country.   
Clinical and epidemiological archived data are recorded on standardized forms.  
Diagnoses are based on clinical examination, along with skin slit smear and 
histopathological examination when available and necessary.  The disease is classified 
according to a simplified Ridley-Jopling criteria. (all three variants of  borderline cases 
are classified simply borderline leprosy; otherwise all other Ridley-Jopling criteria 
remain identical to the standard classification scheme) This study included children aged 
0-14 y/o diagnosed with leprosy between 1987-2001.  Data regarding age, gender, 
leprosy classification, transmission, detection, clinical presentation, presence and class of 
reaction, and disability were abstracted by the primary author of this study.  A minority 
of the charts was abstracted from the standardized charts held at the Kilometer 81 
Mennonite Hospital, as they had not yet been transferred to the permanent archive at the 
Ministry of Health.  A unique study number was assigned to the data collected for each 
patient.  No personal identifiers were recorded.  Data were first recorded on a paper 
abstraction form, and then was transferred to an electronic data base.  Paper records were 
destroyed after the electronic transfer was complete.  Statistical analysis consisted of chi-
squared (χ2 ) tests and odds ratios.  A statistically significant p value was considered to be 
a value of less than 0.05. 
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 RESULTS 
 
A total of 6028 cases of leprosy were diagnosed in Paraguay between the years 1987-
2001.  During this 15 year time period, children aged 0-14 yrs composed 5.1% (308) of 
the total. 
 
Age Distribution 
The study group ranged from 2 to 14 years of age.  The mean age was 10 years and the 
median age was 11years. (n=308) Using population data for Paraguay, both the incidence 
rate and the risk of having leprosy were shown to increase with age.  
 
 
Table 1.  Age Distribution of Children with Leprosy 
Age 
(years) 
No. of new 
cases (%) 
Person-year 
population # 
Incidence 
per person-
year 
Odds Ratio (CI) 
0-4 15 (4.9%) 10,596,670 1.41x10-6 1.00  
5-9 93 (30.2%) 9,774,037 9.52x10-6 6.72 (3.90-11.60) 
10-14 200 (64.9%) 8,846,766 2.26x10-5 15.97 (9.45-26.99) 
Total 308 (100.0%) 29217473 1.05x10-5  
 
Gender Distribution 
The gender ratio of males to females was 1:1.  There were exactly 154 males and 154 
females in the study population. (n=308) 
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 History of Contact 
A positive history of contact meant that it was known from whom the subject contracted 
leprosy.  A positive history in this study population was documented in 86.4% of cases. 
(n=308)  Of these cases, intrafamilial contact accounted for 98.9% of cases. (n=265)  
Extrafamilial sources of contact included 2 neighbors and 1 teacher.  79.3% of children 
had one contact, 14.3% had two, 5.3% had three, and 1.1% had four contacts. (n=265) 
63.3% of the contacts were male.  (n=265) 91.7% of contacts were known to have 
multibacillary (MB) leprosy.  (n=239) 
 
Time to Diagnosis 
The time to diagnosis is defined as the length of time from self-reported onset of leprosy 
to proper diagnosis of leprosy by medical personnel.  The average time to diagnosis was 
1.1 years. (n=293) The time period ranged from 7 days to 11 years.   
 
Type of Leprosy 
29.5% of subjects had tuberculoid leprosy, 37.0% had indeterminate, 15.6% had 
borderline, and 17.9% had lepromatous leprosy.  (n=308) The probability of presenting 
with MB leprosy significantly increased with age.  (p<0.001)  
 
Table 3.  Classification of Leprosy by Age Group 
Paucibacillary (PB) Multibacillary (MB)   
Age Tuberculoid Indeterminate Borderline Lepromatous Total 
0-4  11 3 1 0 15 
5-9 38 37 7 11 93 
10-14 42 74 40 44 200 
Total 91 114 48 55 308 
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 Characteristics of Skin Lesions 
70.5% of subjects presented with multiple lesions at the time of first diagnosis.  25.6% 
presented with a single lesion, and 3.9% presented with primary neurologic deficits. 
(n=305)  84.0% of first lesions appeared in exposed areas of the body. (n=60) 
  
Skin Slit Smear 
28.9% of skin slit smears were positive. (n=114)  In cases that tested positive, 90.9% had 
MB leprosy.  (n=33) 
 
Nerve Involvement/Disability 
Nerve involvement in leprosy is routinely classified using a WHO leprosy disability 
grading system.  It is a simple classification scheme intended for use in the field.  
According to the WHO system, grade 0 disability indicates the absence of anesthesia, 
visible deformity and damage, grade I indicates the presence of anesthesia and the 
absence of visible deformity and damage, and grade II indicates the presence of visible 
deformity and damage. (28)  In this study population, 16.9% of children experienced 
some type of nerve involvement. (n=308) Of these, 88.5% were grade I and 11.5% were 
grade II.  The occurrence of nerve involvement increased with age. (p>0.05) 
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Table 4.  Nerve Involvement with Age(Percent of Total by Each Age Group) 
Presence of 
Nerve 
Involvement 
0-4yrs 5-9yrs 10-14yrs Total (0-14) 
YES 
     Grade I 
     Grade II 
      
    0 (0%) 14 (15.1%) 
14  
0 
 
38 (19.0%) 
32  
6  
 
52 (16.9%) 
46 
6 
 
NO       15 (100%) 79 (84.9%) 162 (81.0%) 256 (83.1%) 
Total 15 (100%) 93 (100%) 200 (100%) 308 (100%) 
 
 
Hypersensitivity Reactions 
1.9% of all children presented with hypersensitivity reactions. (n=308) Type I (reversal) 
reaction was seen in only one case, in a 6 y/o male in indeterminate type leprosy.  The 
remaining 5 children presented with Type 2 (ENL) reaction.   
 
Table 5.  Reactions 
Reaction 0-4yrs 5-9yrs 10-14yrs Total (0-
14yrs) 
YES 
     Type I 
     Type II 
0 0 6 
1 
5 
6 
1 
5 
NO 15 93 194 302 
Total 15 93 200 308 
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 DISCUSSION 
 
Children represented 5.1% of all diagnosed cases of leprosy in the country during the 
time period of this study.  This is far lower than most other populations living in endemic 
areas, in which children generally constitute 20-30% of all cases detected. (1) This 
observation is relevant because the frequency of leprosy in children is thought to be a 
type of epidemiologic index for determining the level of transmission in the population. 
(29)  Following from this, because children in Paraguay develop leprosy relatively 
infrequently, perhaps there is a low background of disease transmission in the population 
as a whole. 
 
The youngest child in this study was 2 years old, potentially representing the minimum 
incubation period for the disease.  This is in accordance with the general consensus that 
the incubation period of M. leprae ranges from 2-5 years. (7,8)   
 
This study found that the incidence rate of leprosy increased with age, a finding reported 
by other studies. (24,27)  This trend might exist because the long incubation period may 
delay onset until later in life, younger children may have less exposure, or perhaps the 
disease is less severe in younger children and therefore goes unreported.  Evidence in 
support of the latter possibility includes reports of self-healing leprosy lesions that have 
been documented in children. (8) 
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 The male to female ratio in this study was 1:1, a trend in that has been widely observed in 
other studies of pediatric leprosy. (7,27)  However, some studies of children have shown 
a male predominant gender ratio. (25,26,29).  In sum, the gender ratios reported in 
children have been somewhat variable.  In contrast, in the adult population, a male to 
female predominant ratio has been well-established. (6,7,8) This skewed ratio in adults 
could exist because adult women may face more barriers to healthcare and men may have 
a greater risk of exposure as they are more mobile than women in traditional societies.  
The 1:1 gender ratio in children could exist because boys and girls in the same home 
would theoretically be exposed to similar environments, have similar risk factors for 
contracting the disease, and share equal access to health care.  The 1:1 pediatric gender 
ratio found in this study likely implies that males and females are biologically equally as 
likely to contract the disease, and that the ratio skewed toward males in adults in due to 
socio-cultural constructs.  An alternative explanation to the existing gender distribution 
could be that testosterone may have some role in triggering the development of leprosy; 
this could explain why post-pubertal males have a higher prevalence of disease compared 
with their female counterparts, though there is no evidence in the literature to support this 
theory. 
 
This study found that 86.4% of patients had a positive history of contact with a leprosy 
patient, a much higher proportion than seen in other studies (24-26,29).  Of these 
subjects, 98.9% cited their contact as being intrafamilial.  These figures imply that close 
and prolonged contact with an infected individual is necessary for transmission because 
most people knew from whom they caught the disease and this person was usually a 
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 family member.  If transmission occurred through more casual means, say through the 
sneeze of a stranger sitting next to an individual on a bus, the cases would be much less 
likely to be able to recall an ill contact and thus the proportion of cases with a positive 
history of contact would be much smaller.  The high proportion of patients in this study 
reporting a positive history of contact could also imply that a high level of disease 
awareness exists among Paraguayans diagnosed with leprosy in Paraguay; if the cases did 
not know the typical signs and symptoms of the disease, they would probably be less 
likely to be aware of close contacts with leprosy.  91.7% of contacts had MB leprosy.  
This conforms with the logic that MB patients have a much higher bacillary load and are 
much more likely to be a source of contagion compared to a person with PB leprosy. 
 
The average time to diagnosis was 1.1 years.  This is comparable to several other studies 
of children in endemic areas. (24,25,29)  It could be argued, however, that the ideal time 
to diagnosis should be much shorter than one year, considering that in the time period of 
a year, a child could conceivably already have suffered irreversible nerve damage.  A 
further reduction in time to diagnosis should be a priority since early detection is a 
cornerstone of a successful leprosy control program.   
 
In this study, the probability of presenting with MB leprosy significantly increased with 
age.  This phenomenon could potentially be explained by the fact that MB leprosy 
generally takes more time develop; in other words, as a case of MB leprosy first evolves 
through more benign stages of the disease with a lighter bacillary load and fewer lesions, 
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 perhaps the disease goes unnoticed and undiagnosed.  Then, by the time a florid case of 
MB leprosy presents, the child has reached an older age. 
 
The majority of subjects presented with multiple lesions at the time of diagnosis.  Most, 
likely, one could assume that a subject first developed one lesion, then went on to 
develop additional lesions at a later date.  Ideally, the subject would have been diagnosed 
after the appearance of single lesion and this data may imply that a more rapid approach 
to disease detection should be emphasized. 
 
 The vast majority (84.0%) of patients reported the first lesion occurring in an exposed 
area of the body, a finding well-supported by other reports (24-26,29).  This could be 
explained by M. leprae’s predilection for the cooler areas of the body.  Unexposed areas 
of the body that are normally covered with clothes potentially represent a warmer, more 
hostile environment for the organism to grow.  
 
The majority of subjects presented with negative skin slit smears.  This observation is 
consistent with the fact that the majority of subjects in the study had PB leprosy, a class 
of disease with a light load of bacilli that is not expected to be positive on skin slit smear 
examination. 
 
16.9% of children in this study experienced some type of nerve involvement at time of 
presentation.  This observation is similar to the findings of the WHO leprosy BCG trial in 
Burma in which 20.4% of new cases were shown to present with neural involvement. 
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 (30)  In this study, those children who did suffer nerve involvement, tended to experience 
the mildest type of disability.  Again, this finding is consistent with other observations 
that have found severe disability and deformity to be rare in children. (7) 
 
The frequency of nerve involvement tended to increase with age in this study population, 
a finding similar to other investigations. (27,31)  This finding is logically explained by 
the fact that nerve involvement generally occurs as a function of time; therefore, children 
who present with leprosy at an older age probably have had the disease for a greater 
length of time and would logically be at a greater risk of developing nerve involvement. 
 
1.9% of children presented with hypersensitivity reactions.  Most other studies of 
childhood leprosy have similarly found hypersensitivity reactions at time of presentation 
to be relatively rare. (25,27,29) 
 
When children did present with a reactional episode in this study, it was of the Type 2 
(ENL) Reaction the majority of the time.  This is in contrast to other studies that have 
found Type I Reversal Reaction to be more common (24,29).  In general, Reversal 
Reaction is more commonly seen in borderline leprosy, while ENL Reaction is more 
commonly experienced by patients with lepromatous leprosy.  In this study population, 
the proportion of subjects with borderline and lepromatous leprosy were approximately 
equal and would not account for the difference seen in types of reactional episodes.  It 
remains unclear why the most common class of reaction in this study was of the ENL 
type. 
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It should also be noted that the annual incidence of leprosy in this population was 
relatively steady during the time period of the study.  The great decline expected in 
leprosy incidence in the decades following the introduction of MDT was not seen in this 
population, mimicking macro-level incidence trends. 
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 AFTERTHOUGHTS  
 
I. Suggested Points of Improvement 
Though data was not specifically collected for the purposes of evaluation and 
improvement of leprosy healthcare delivery in Paraguay, the time I spent in country 
immersed in clinical care, training, and research related to leprosy provided ample time 
for observation, resulting in several points for discussion and suggested points of 
improvement of the leprosy program in Paraguay. 
 
1. The vertical versus integrated care model 
As mentioned earlier, the WHO advocates for an integrated system of leprosy 
management in endemic countries. (6)  In other words, leprosy care should be fully 
integrated into the general healthcare system in the country.  This is in contrast to older 
vertical programs consisting of leprosy specialists.  The logic behind this approach is that 
the general health services are widely distributed and have close and frequent contact 
with the local community.  Following from this, involving general practitioners in leprosy 
control will improve case-finding and increase awareness of the disease in the local 
community.  Over time, this approach should prove to be cost-effective considering that 
the long-term operational costs of an integrated program should be much less than that of 
a specialized leprosy program. (32) 
 
At the time this study was conducted, Paraguay was in a state of changing from the older 
vertical system to the newer integrated treatment of leprosy.  The vast majority of new 
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 diagnoses of leprosy were still being made by either the Ministry of Health leprosy 
department or by several leprosy specialists in the country.  Very few diagnoses were 
made by generalist physicians.  The common anecdote told by leprosy patients in 
Paraguay is that after first recognizing unusual symptoms, they would go to their family 
doctor who would misdiagnose the disease as a skin fungus, prescribe a cream that had 
no effect, and that the correct diagnosis would generally not occur until after about one 
year after initiation of disease manifestations.  This common story is precisely why a 
more integrated approach to leprosy care is imperative.  If generalist physicians have the 
expertise to diagnose and manage leprosy autonomously, the one year time to diagnosis 
would be reduced as would the risk of developing irreversible sequelae from the disease.   
 
Some progress toward a more integrated system was being made in Paraguay at the time 
of the study.  For example, several physicians advocated for improved leprosy training in 
a prominent medical school in the country’s capital in order to produce generalists who 
could diagnose and manage leprosy on their own.  Proper training in leprosy management 
in medical schools is essential in order to produce generalist physicians competent in 
leprosy care.  However, the lag time between training and practicing in the community is 
potentially great, and the impact on the population might not be seen for several years.  It 
appeared as though additional strategies needed to be employed in order to fully 
transform leprosy care into an integrated model of care.  Several suggestions for 
improvement in this area follow: 
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 • Rigorous leprosy training in all medical school (both private and public) 
throughout the country, perhaps including day trips or week-long rotations at the 
Ministry of Health leprosy clinic and lab 
• Rigorous leprosy training in medical residencies throughout the country 
• Regular training courses for practicing generalists and dermatologists 
 
2. Health Education 
Health education, as mentioned previously, is a crucial component to a leprosy control 
program.  The patient must be knowledgeable about his disease in order to complete 
treatment properly, deal with the potential stigma of the disease, minimize sequelae of the 
disease, and recognize potential disease in contacts.  Likewise, education of patient 
contacts and of the general public is important in order to decrease the stigma of the 
disease in society and to quickly recognize symptoms in new patients.  At every site 
visited during the research and training period, excellent health education was being 
delivered to patients, family members of patients, and community members.  Key aspects 
including the etiology of the disease, the side-effects of medications, proper recognition 
and care for skin ulcers related to leprosy, and the stigma and common myths associated 
with the disease were regularly addressed in a language appropriate for the audience.  
The level of dedication seen among the health educators was impressive, specifically at 
the Ministry of Health Leprosy Department, the Kilometer 81 Mennonite Hospital, and 
several smaller district hospitals near the country’s capital.   Despite the heroic efforts of 
leprosy health educators in the country, a significant level of stigma and misconceptions 
associated with the disease still exist in the country in the general public.  Though 
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 financial constraints are surely a challenge, increasing leprosy health messages to the 
general public would be ideal.  Several methods by which to accomplish this include: 
 
• Public service announcements on TV and radio 
• Using a local celebrity or well-respected individual in the public eye to deliver 
such messages 
• Health education talks on leprosy in schools and workplaces 
 
 
II. A Day without Leprosy? 
Though incredible achievements have been made in the realm of leprosy control with a 
dramatically decreased prevalence in recent decades, the possibility of complete disease 
eradication seems unlikely.  A lack of vaccine, a vague knowledge of transmission, the 
long incubation period, a lack of a rapid, simple diagnostic test, and the long duration of 
treatment make leprosy an unlikely candidate for disease eradication. (33) In order to 
strive for the day of possible eradication in the future, more research is essential in the 
areas of leprosy epidemiology and biology to better understand and tackle this ancient 
disease we ironically know so relatively little about.  Though leprosy may seem here to 
stay at least in the immediate future, maximally effective control of the disease on the 
population level is possible and the continued political and community-level commitment 
to achieve this short-term goal is imperative. 
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 APPENDIX 
Interview with Dr. Carlos Wein, Leprosy Clinician and Researcher 
 
Conducted by Jessica Kattan 
Hospital Mennonita, Kilometro 81 
Translated from Spanish to English by Jessica Kattan 
23 July 2002 
 
Dr. Carlos Wein was raised in Paraguay as a member of a close-knit Mennonite 
community outside the country’s capital.  As a young man he was inspired by the work of 
Father Damien, a Belgian priest who selflessly provided spiritual guidance and medical 
care for hundreds of leprosy victims forcefully confined to the island of Molokai, Hawaii 
in the late 1900s. (17)  Driven by this inspiration, Dr. Wein studied medicine at the 
National University of Asuncion, Paraguay.  After graduating at the top of his medical 
school class and completing training in general surgery at the same institution, he went 
on to become medical and religious director of the Kilometer 81 Mennonite Hospital, a 
prominent leprosy care center and general hospital run by the Mennonite community in 
Paraguay.  Since taking this post, he has served countless leprosy patients free of charge, 
conducted research and published voluminously on leprosy, invented new surgical 
techniques for leprosy-related procedures, taught medical students, and has worked as an 
advocate in the public health community to improve leprosy control and decrease stigma 
of the disease. 
 
Upon hearing the word “leprosy,” most people, unfamiliar with the disease, immediately 
think of severe deformity and suffering.  In your experience, how do new cases usually 
present? 
 
Eighty to ninety percent of new cases present with skin problems, lacking any noticeable 
markings of the face, in the hands, or on the feet.  This means that when you are looking 
for new cases, you should not exclusively expect ulcers, mutilations, and deformities. 
Instead, attention should be focused on skin lesions that could be very mild or 
insignificant. 
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In the present day, do you still see cases of people who are very deformed or is this a 
thing of the past? 
 
About five to ten percent [of patients] present with irreversible lesions. 
 
Currently, what is the stigma related to leprosy? 
 
People still think that leprosy is a punishment from God, or from the devil, or a curse that 
you receive for a sin that you need to pay or that you need to pay for ancestors.  People 
believe a lot in superstition—the belief that there is something supernatural that causes 
leprosy.  That means that curing leprosy with a simple pill is very novel for the people 
because they expect an act of exorcism or some way to take the evil spirit or curse out of 
the person.  There is a lot left to do so that people understand that leprosy is exclusively 
an infectious disease.  It is a bacillus that causes problems, and working with the bacillus 
we can resolve the problem.  It is very difficult to modify [these superstitious beliefs] 
because [they are] stuck in the subconscious of the people. 
 
Can you give me an extreme example of how stigma manifests itself in the lives of the 
patients? 
 
The case that surprised me is the case of a man who was in leprosy treatment and was 
visited by the priest of the community.  This priest said to the wife and three daughters of 
the patient that he should go into seclusion because he was a leper.  When this man came 
to see me, I told him that what the priest said was not true.  However, the family told me 
that, in the end, they would do what the priest told them to do.  I felt surprised that they 
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 would listen more to the priest than to me.  They told me that leprosy is a biblical 
disease—that priests know more about the disease and its treatment than the doctors, and 
that the doctors should not involve themselves in a matter that is not medical.  Leprosy is 
a spiritual thing, they said.  He had to leave his family and he was living for months far 
from home.  Finally, the family came to him and asked him to come back home for the 
following reasoning:  We will forgive you and you can come back.  When I asked the 
patient, what things there were to forgive, he told me calmly, “The fact that I am a leper.  
I need society to forgive me.  Everyone knows I carry something that needs forgiveness 
or else face rejection from society.” 
 
Additionally, there have been various occasions in which people have tried to burn down 
the houses of [leprosy] patients or tried to burn the patients also.  The last case I 
remember was six years ago.  It was an 80-year-old woman.  They set fire to her house, 
but she was able to escape.  The community made her a little despicable shack to live in, 
surrounded by barbed wire so that no one could enter or leave; it didn’t have a gate.  
These are testaments to the stigma of leprosy.   
 
How do patients respond to hearing the diagnosis of leprosy? 
 
There are two types of reactions.  On the one hand, there are those who come with the 
suspicion that they have leprosy and we confirm that suspicion. First, this type of patient 
thinks of his family and what will happen to his children.  Many start to cry.  They accept 
that they will suffer, as long as the children do not know and do not suffer.  We have 
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 people that try to commit suicide.  And when we look a little deeper, immediately after 
hearing the diagnosis, they feel punished by God.  So, we feel the necessity to explain to 
them that that has nothing to do with it, with God. 
 
On the other hand, the patients who have participated in health education talks in 
schools—about the treatment, about how leprosy is not a curse of God—it is incredible 
the positive reaction they have.  They are so positive, saying “give me the medicine 
because I know what I have and I know that I will get better”, instead of being 
embarrassed.  They see it with completely different eyes.  This confirms to me that this is 
the key point to managing leprosy—not just the diagnosis and treatment, but in the sense 
of understanding how the patient feels.  This is the starting point from which to manage 
leprosy well.  It is essential not just to teach the patients about the treatment, but to keep 
them calm. 
 
 
How would you summarize the leprosy situation in Paraguay compared with the past and 
with other countries? 
 
As far as the detection of new cases, the situation has not changed.  We continue to have 
many new cases without achieving the reduction that we were waiting for 15 years ago 
with the implementation of multi-drug therapy.  The detection of new cases depends a lot 
on the type of work implemented in each district.  In the majority of places, detection of 
new cases works very well.  We are improving in other places where we are not 
functioning as well.  Once the patients are identified as sick, we have been commended 
by the World Health Organization and others on the excellent follow-up of patients.  
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 There are very few people lost to follow-up.  Follow-up of patients is done very 
regularly.  If the patient does not come, they are found, and they finish their course of 
therapy. 
 
Compared with other countries, there is a strong influence of NGOs, like the Mennonite 
Hospital.  That means that the programs have a lot of stability that is not affected by 
political or financial changes in the country.  Our country has a lot less leprosy than in 
Brazil.  They treat in a more decentralized way. They continue to have problems in 
access and follow-up. 
 
In Paraguay, are some groups more affected by leprosy than others? 
 
It is notable that indigenous groups do not have leprosy.  But, in the general population, 
there is no one group that has more leprosy.  Urban and rural, and east and west seem to 
have the same statistics. 
 
In Paraguay, the population of people over 45 years old has more cases of leprosy than 
younger age groups.  Do you have any theories? 
 
The greatest risk for exposure occurs when people start to work or go away to school. 
Before that, people stay close to their families.  So, the greatest exposure happens in 
those twenty years or older.  Plus, you need to consider the incubation period of leprosy. 
It ranges from 3-40 years.  The average [incubation period] is about 15-50 years.  So, if 
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 you add 20 years at age of exposure plus the incubation period, you get about 40 years 
old. 
 
Currently what is the situation of leprosy patients who live in rural areas? 
 
In general, most patients have access to care in the medical facility that is closest to them.  
If they cannot go to the health centers, people go to visit them in their homes.  The 
distance to patients’ homes in our country is not an impediment to give 100% treatment. 
 
The outpatient treatment [of leprosy] started in the 1960s.  Before, it was routine to take 
people to places where they would live for the rest of their lives.  This transformation 
converted the treatment of leprosy from the leper colonies to an outpatient treatment.  
After 1987 the treatment advanced a lot with teams going to the interior of the country so 
that the majority of patients have access [to care].   
 
Why isn’t the incidence of leprosy dropping, even though we have had good therapy for 
years and the prevalence of the disease has dropped dramatically? 
 
We still cannot say for sure that there has been a reduction in the reservoir.  The multi-
bacillary patients who are treated have had months or years of opportunity to spread the 
bacillus.  There are studies in India that show that the bacteria can stay alive on the 
ground for up to five months in a viable form.  This could be a possible fountain of 
contagion.  Recently, evidence has been presented that shows that there can be healthy, 
asymptomatic carriers of the disease.  It seems reasonable that the long incubation period 
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 and the delayed appearance of multi-bacillary cases could account for why we keep 
seeing so many cases.  Even if we presumably treat the last leprosy patient, we could 
keep getting cases that this “last” patient infected in the past for the next 20-30 years.  So, 
there is a general consensus that only infectious disease that have vaccines have been 
eradicated. We do not have a vaccine for leprosy. 
 
Do you think that leprosy will be completely eradicated some day? 
 
Judging from the situation in the world, despite multi-drug therapy, there are no secure 
signs that [leprosy] is really going to be eradicated. 
 
Have you ever been scared of contracting leprosy? 
 
I have dreamed various times that I had leprosy and I have woken up very upset.  But, the 
illness itself has not really frightened me too much, nor the skin lesions, nor taking the 
treatment.  What really scares me is having leg ulcers and neuritis secondary to 
reactions—that does worry me.  But, if we make an early diagnosis and proper treatment, 
no one should be terrified of this disease. 
 
What should be the fields of research for the future? 
 
I think more research should be done in the realm of reactions.  I would not focus on 
earlier diagnostic tests.  We are already doing diagnosis at an early stage.  We do not 
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 have microbial resistance.  But the reactions—we will probably need to find a way to 
eliminate the remnants of the bacteria so that the immunologic reactions do not occur.  
This is the process that leads to nerve problems.  Even without significant clinical 
manifestations, the nerves atrophy and leave permanent sequelae.  The medical 
management of this condition with only steroids is often insufficient. Then, we must 
watch the patients develop deformities, even after doing nerve surgery and giving them 
steroids. 
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